Missoula, MT, October 10, 2023 – With a new NIAID contract, Pritzker Molecular Engineering Prof. Aaron Esser-Kahn will work with UChicago faculty and biotech company Inimmune Inc. to develop a flu vaccine that has fewer side effects for vulnerable populations.
About Inimmune Corporation
Inimmune Corp. (Missoula, MT) is a privately held biotechnology company focused on the discovery and development of innovative immunotherapeutics, vaccine adjuvants, and vaccines. Inimmune is harnessing the human immune system to create safe and effective treatments for allergy, infectious disease, autoimmunity, and cancer. Their laboratories and offices are housed in the Montana Technology Enterprise Center (MonTEC) in Missoula.
For more information on Inimmune’s research and development of novel vaccine adjuvants and delivery systems, please visit www.inimmune.com.